VIMTALABS638.50

Vimta Labs Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUVENTAKEMcap ₹1,416 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
31/12/2024
Revenue from Operations278.3318.2318.3336.1
Other Income1.43.44.03.1
Total Income279.7321.6322.3339.2
Expenses
+ Cost of Materials Consumed78.973.776.275.4
+ Changes in Inventories0.30.10.10.1
+ Employee Benefit Expense76.091.199.395.6
+ Finance Costs1.52.62.12.0
+ Depreciation & Amortisation23.330.734.234.4
+ Other Expenses42.858.455.953.2
Total Expenses222.8256.6267.8260.6
EBITDA80.394.986.8111.9
EBIT57.064.252.677.5
Profit
PBT before Exceptional Items56.965.054.578.6
+ Exceptional Items-1.20.00.00.0
Pretax Income55.765.054.578.6
+ Current Tax15.419.116.918.9
+ Deferred Tax-1.0-2.2-3.40.6
Tax Expense14.416.813.519.5
Net Income41.348.241.061.4
+ Net Income — Continuing Ops41.348.241.059.2
+ Net Income — Discontinued Ops0.00.00.02.2
+ Other Comprehensive Income-0.2-0.0-0.2-0.2
Total Comprehensive Income41.148.140.861.1
Per Share
Basic EPS18.7021.7718.5127.65
Diluted EPS18.3221.3518.2427.30
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.00.00.03.0
+ Tax — Discontinued Operations0.00.00.00.8
Other Comprehensive Income — detail
+ Items NOT to be Reclassified to P&L-0.0-0.3-0.3
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.1-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations18.7021.7718.5126.66
Diluted EPS — Continuing Operations18.3221.3518.2426.31
Basic EPS — Discontinued Operations0.000.000.000.99
Diluted EPS — Discontinued Operations0.000.000.000.99
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit199.1244.3242.0260.7
Gross Margin %71.5476.7976.0377.56
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)56.965.054.578.6
− Exceptional Items (reconciliation)-1.20.00.00.0
Net Income Adj (tax-effected)42.248.241.061.4
EPS Adj19.1121.7718.5127.65
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital4.44.44.44.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.